Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma

Alessandra Venanzi, Andrea Marra, Gianluca Schiavoni, Sara G. Milner, Roberto Limongello, Alessia Santi, Valentina Pettirossi, Simona Ultimo, Luisa Tasselli, Alessandra Pucciari, Lorenzo Falini, Sofia Sciabolacci, Maria Paola Martelli, Paolo Sportoletti, Stefano Ascani, Brunangelo Falini, and Enrico Tiacci

Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.

Note: Supplementary data for this article are available at Blood Cancer Discovery Online (https://bloodcancerdiscov.aacrjournals.org/).

A. Venanzi, A. Marra, and G. Schiavoni contributed equally to this article.

B. Falini and E. Tiacci are cosenior authors of this article.

Corresponding Authors: Enrico Tiacci, Institute of Hematology and Center for Hemato-Oncology Research (C.R.E.O.), University and Hospital of Perugia, Perugia, 06132, Italy. Phone: 3907-5578-3294; Fax: 3907-5578-3834; E-mail: enrico.tiacci@unipg.it; and Brunangelo Falini, brunangelo.falini@unipg.it

Blood Cancer Discov 2021;2:216–25
doi: 10.1158/2643-3230.BCD-20-0203
©2021 American Association for Cancer Research.

ABSTRACT

Clonal hematopoiesis predisposes to hematologic malignancies. However, clonal hematopoiesis is understudied in classic Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 cHL cases by sequencing microdissected tumor cells and matched normal cells from blood and/or lymph nodes. Five patients had blood and/or tissue clonal hematopoiesis. In three of five patients (all failing first-line therapy), clonal hematopoiesis spread through the tissue microenvironment extensively, and featured mutant \( DNMT3A^{R882H} \), \( KRAS^{G60D} \), and \( DNMT3A^{R882H} + TET2^{Q1274\ast} \) in 33%, 92%, and 60% of non-neoplastic cells, respectively. In the latter case, \( DNMT3A/TET2 \)-mutant clonal hematopoiesis seeded the neoplastic clone, which was infected by the Epstein–Barr virus and showed almost no other somatic mutations exome-wide. In the former case, \( DNMT3A \)-mutant clonal hematopoiesis did not originate the neoplastic clone despite dominating the blood and B-cell lineage (∼94% leukocytes; ∼96% mature blood B cells), yet led to \( NPM1 \)-mutated acute myeloid leukemia 6 years after therapy for cHL. Our results expand to cHL the spectrum of hematologic malignancies associated with clonal hematopoiesis.

SIGNIFICANCE: Clonal hematopoiesis can be present in the cHL tissue, can give rise to the tumor clone, and can spread to large parts of its microenvironment. Even when massive, clonal hematopoiesis does not always give rise to the neoplastic clone of multiple myeloid and lymphoid neoplasms occurring in the same patient.

INTRODUCTION

Clonal hematopoiesis of indeterminate potential (CHIP) is promoted by the age-dependent stochastic occurrence of mutations in driver genes (e.g., \( DNMT3A \) and \( TET2 \)) that confer a fitness advantage to hematopoietic stem/progenitor cells (HSPC; ref. 1). CHIP is frequent in the elderly and predisposes to hematopoietic neoplasms mostly of myeloid or T-cell lineage. However, the role of CHIP in classic Hodgkin lymphoma (cHL) remains largely unexplored. Here, we report the detection of clonal hematopoiesis in the tissues of five patients with cHL, and characterize the molecular and clinical features of these cases.
Clonal Hematopoiesis in Classic Hodgkin Lymphoma

Prevalence of Clonal Hematopoiesis

To assess the frequency of clonal hematopoiesis in patients with cHL, we interrogated our previous whole-exome sequencing (WES) data from non-HRS cells of 34 cHL cases, which we used as a matched normal counterpart to call somatic mutations in HRS cells but not in matched normal cells, uncovering several new mutated genes driving lymphoma cell growth and immune evasion (14–17). Clonal hematopoiesis has been detected in HSPCs harvested from 9 of 64 (14%) cHL relapsed patients of unknown age undergoing autologous transplantation (18). However, no data exist on the potential presence of clonal hematopoiesis in the microenvironmental and/or neoplastic components of cHL tissue. Here, we assessed clonal hematopoiesis frequency and tissue distribution in 40 well-characterized cHL cases largely studied at disease onset, and also describe the surprising findings on a young cHL patient with massive CHIP who developed AML following therapy for cHL.

RESULTS

Tissue Distribution of Clonal Hematopoiesis in Patients with cHL

We then dissected the distribution of clonal hematopoiesis through the cHL tissue in each of these five cases. Case 1 was notable for the development of cHL followed by AML and will be described separately in the next section.

Case 2 was a 31-year-old male, who presented with stage IVB at onset and was studied at progression following both doxorubicin hydrochloride, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) and salvage autologous hematopoietic stem cell transplantation (ASCT). He had a mixed cellularity cHL negative for Epstein–Barr virus (EBV) infection, in which a KRAS(G12D) mutation massively expanded throughout reactive tissue cells (VAF = 45.9%) while being absent in HRS cells; conversely, the latter carried 57 somatic protein-changing mutations upon WES (ref. 15; Fig. 1A; Supplementary Table S2).

Case 3 was an 83-year-old male, who had an EBV-positive mixed cellularity cHL, stage IIB, and died of chemotherapy complications. Targeted sequencing of the onset tissue biopsy documented a likely pathogenic mutation of CBL (G377S; ref. 19) that was present at a relatively low VAF (2.5%) in reactive tissue cells and was absent in HRS cells (Supplementary Fig. S2; Supplementary Table S2).

Case 4 was an 81-year-old female. She had an EBV-negative nodular sclerosis cHL, stage IIA, and remained free from progression 64 months after doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) polychemotherapy. She carried a TET2(G1487W) mutation in blood leukocytes (VAF = 3.2%) but not in reactive tissue cells or in HRS cells; the latter had 97 somatic mutations on WES (ref. 15; Fig. 1B; Supplementary Table S2).

Case 5 was a 73-year-old male, who presented with mixed cellularity cHL stage IIA and was studied at relapse 35 months after six cycles of ABVD. In his tissue biopsy, DNM3A(R882H) and TET2(Q1274*) spread considerably in reactive tissue cells (VAF = 30% and 8.4%, respectively); however, unlike the previous cases (including case 1 also showing DNM3A(R882H), a mutant clonal hematopoiesis; see next section), both mutations...
Table 1. Prevalence and tissue distribution of clonal hematopoiesis in patients (n = 40) with cHL

<table>
<thead>
<tr>
<th>CH present</th>
<th>Years of age</th>
<th>Pt.#</th>
<th>Time of sampling</th>
<th>Progressed after first-line chemotherapy</th>
<th>Gene mutation</th>
<th>VAF in whole blood</th>
<th>VAF in microdissected Reactive lymphoid cells</th>
<th>VAF in whole tissue section</th>
<th>VAF in bone marrow</th>
<th>VAF in blood T cells</th>
<th>VAF in blood B cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO (n = 35)</td>
<td>Median 35 Range 15–75</td>
<td>30</td>
<td>2nd relapse</td>
<td>YES</td>
<td>KRAS G60D</td>
<td>NA</td>
<td>45.9% ND 22.9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>83</td>
<td>Onset</td>
<td>Not evaluable</td>
<td>CBL G375S</td>
<td>NA</td>
<td>2.5% ND NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>81</td>
<td>Onset</td>
<td>NO</td>
<td>TET2 N1487fs84</td>
<td>3.2% ND NA</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YES (n = 5)</td>
<td></td>
<td>73</td>
<td>Onset</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>NA</td>
<td>NA</td>
<td>32.4% 22.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1st relapse</td>
<td>YES</td>
<td>TET2 Q1274*</td>
<td>NA</td>
<td>30% 43% 37.9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>45</td>
<td>Onset</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>47% 16.4% ND 12.2%</td>
<td>45.2% 6.9% 48%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NPM1 W288CfsTer12</td>
<td>NA</td>
<td>ND</td>
<td>40.6% ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PTPN11 E76K</td>
<td>ND</td>
<td>ND</td>
<td>25.7% ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 ITD</td>
<td>NA</td>
<td>NA</td>
<td>0.14* NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3ITD</td>
<td>NA</td>
<td>NA</td>
<td>0.11* NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 N417Y</td>
<td>NA</td>
<td>ND</td>
<td>36.9% NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 D419H</td>
<td>NA</td>
<td>ND</td>
<td>35.7% NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SOCS1 PB3Afs*25</td>
<td>NA</td>
<td>ND</td>
<td>98.6% NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CH, clonal hematopoiesis; NA, not available; ND, not detected.

*Mutant/wild-type ratio by fragment length analysis.
Figure 1. Tissue involvement by clonal hematopoiesis in cHL. A, In this EBV-negative mixed cellularity cHL (case 2), the reactive tissue microenvironment (mostly represented by T cells—not shown) belonged to clonal hematopoiesis almost entirely, as it featured a KRAS<sup>G60D</sup> mutation at a VAF of 45.9%. However, the HRS cell clone developed from a B cell not belonging to clonal hematopoiesis, after acquiring a JAK2 gain and a B2M mutation (genetic lesions typical of cHL), along with 55 additional somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+55” in the HRS cell nucleus). Myeloid involvement by clonal hematopoiesis is presumptive because we did not have a blood or bone marrow sample from this patient to formally confirm it. HSC, hematopoietic stem cell. B, In EBV-negative nodular-sclerosis case 4, clonal hematopoiesis (carrying TET2<sup>N1487Ifs84</sup>, which was detected in whole-blood leukocytes and likely involved the myeloid lineage (only or mainly), did not spread through either the lymphoid HRS cell clone or its reactive tissue microenvironment. Also indicated are mutations of two genes (ITPR3 and GRM7, recurrently targeted in cHL; ref. 15) that were found in HRS cells but not in blood leukocytes of this cHL case, along with an additional 95 somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+95” in the HRS cell nucleus). (continued on next page)

were carried over in the HRS cell clone, which was infected by EBV and otherwise had only three somatic mutations detected by WES (ref. 15; Fig. 1C; Supplementary Table S2). Retrospective targeted sequencing of whole sections from the formalin-fixed lymph node biopsy at cHL onset of case 5 documented the same DNMT3A<sup>R882H</sup> and TET2<sup>Q1274*</sup> mutations at 32% and 22% VAF, respectively (Table 1 and Supplementary Table S2), indicating a consistent association of microenvironmental clonal hematopoiesis with cHL pathogenesis in this patient and confirming the inability of chemotherapy to clear clonal hematopoiesis (9).

Trajectories of Clonal Hematopoiesis in a cHL Patient Sequentially Developing AML

Case 1 was a 45-year-old man diagnosed with nodular sclerosis, stage IVB cHL, negative for EBV (Fig. 2A–C). After failing polychemotherapy with ABVD, he was successfully salvaged with a second-line regimen (ifosfamide, gemcitabine,
vinorelbine; IGEV) and ASCT, followed by consolidating radiotherapy. Almost 6 years after cHL diagnosis, he developed AML with clonal mutations of NPM1 and DNMT3A<sup>R882H</sup>, and subclonal PTPN11 and FLT3-ITD mutations. The bone marrow karyotype was normal and no mutations of TP53 or PPM1D were identified, in contrast to what is typically observed in therapy-related AML (Supplementary Data). Retrospective analysis of blood DNA at cHL diagnosis revealed DNMT3A<sup>R882H</sup> at high VAF (47%, i.e., ~94% of blood cells), indicating massive clonal hematopoiesis from which AML later arose after acquiring the NPM1 mutation (Fig. 2D; Table 1; Supplementary Table S2), which is typically associated with de novo AML (20).

To deconstruct DNMT3A<sup>R882H</sup> distribution through lymphopoiesis, we sequenced purified mature B and T cells from a fresh peripheral blood sample taken during remission from AML. DNMT3A<sup>R882H</sup> was observed in almost all B cells (VAF = 48%) and some T cells (VAF = 6.9%; Table 1; Supplementary Table S2). Targeted sequencing of the cHL neoplastic and nonneoplastic components microdissected from a lymph node biopsy (Supplementary Fig. S1) documented DNMT3A<sup>R882H</sup> in a considerable proportion (VAF = 16.4%) of reactive cells mostly of T-cell origin (Fig. 2C; Supplementary Fig. S1) but, surprisingly, its absence in HRS cells (Fig. 2D; Table 1; Supplementary Table S2). The latter cells carried clonal STAT6 and SOCS1 mutations typical of cHL (15).

In general, clonal hematopoiesis appeared more frequently in cases studied in the lymph node (4/15, 27%) versus the blood (2/27, 7%; cases 1 and 4 were studied in both compartments). However, this difference was not significant (Fisher exact test \( P = 0.16 \)) and could have been confounded by the significantly older age of the former versus the latter group (mean of 56 and 37 years, respectively; unpaired \( t \) test \( P = 0.003 \)).

In all three cases (1, 2, and 5) with significant clonal hematopoiesis spreading (VAF ≥10%) through the mostly lymphoid microenvironment, the latter was found to be polyclonal upon T-cell receptor gamma gene rearrangement analysis (Supplementary Fig. S3), confirming that the mutations underlying clonal hematopoiesis had occurred in a bone marrow stem or progenitor cell before T-cell lineage commitment. All three patients progressed after first-line chemotherapy, as opposed to 11/35 (31%; Fisher exact test \( P \) value 0.043) evaluable patients with absent or nonextensive clonal hematopoiesis in the tumor tissue, who had similar clinical characteristics and received a no less intense first-line therapy (Table 2).

**DISCUSSION**

Here, we provided an initial characterization, largely by WES, of clonal hematopoiesis prevalence and histogenetic distribution in cHL cases mostly studied at disease onset. Clonal hematopoiesis was readily observed in elderly patients with cHL but could be detected also in younger ones, and an even higher prevalence might emerge upon deeper targeted sequencing. CHIP-associated mutations displayed a diverse distribution pattern through the HRS cell and microenvironmental tissue components, with significant representation in both (case 5, Fig. 1C), in only the microenvironment (case 2, Fig. 1A; case 1, Fig. 2D), or in none of them (case 4, Fig. 1B; and also case 3 with little spreading in reactive tissue cells, Supplementary Fig. S2). Notably, in the three patients with significant tissue involvement by clonal hematopoiesis, who all failed first-line chemotherapy, a large part of the
Figure 2. Trajectories of clonal hematopoiesis in a patient sequentially developing cHL and AML (case 1). A–C, Nodular sclerosis cHL lymph node biopsy immunostained (red labeling) for CD30 shows various HRS cells strongly expressing this cHL diagnostic marker [A]. Immunostaining for the B-cell-specific transcription factor PAX5 [B] shows nuclear positivity in a multinucleated Reed–Sternberg cell (black arrow) and to a higher intensity, in sparse bystander B cells (one indicated by the red arrow). In C, CD3 immunostaining highlights the abundant reactive T cells in the microenvironment surrounding HRS cells. D, Spreading of the DNMT3A<sup>R882H</sup> mutation: (i) through preneoplastic hematopoiesis in the bone marrow and blood, with multilineage myeloid cell, B-cell, and T-cell involvement and then (ii) through the neoplastic tissues of AML and cHL, in the latter involving reactive tissue cells (mostly T cells) but not HRS cells. Also indicated are the genetic lesions leading to the development of the AML clone (NPM1 mutation) and the HRS cell clone (STAT6 and SOCS1 mutations), arising, respectively, from a myeloid progenitor belonging to clonal hematopoiesis and a mature B cell not belonging to clonal hematopoiesis. HSC, hematopoietic stem cell.
DNMT3A mutations were found exclusively in EBV+ fuse large B-cell lymphomas (DLBCL), presumably clonal of the tumor cell clone of B-cell lymphomas (10), and those T-cell lymphomas, mutations of are less prevalent in TET2 (Supplementary Discussion). While relatively frequent in fiers might contribute to the development of this lymphoma components might contribute to the development of this lymphoma and not progressing after first-line therapy). COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinblastine sulfate. Outcome was not available for one patient (UPN40) and not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity. Follow-up was not available for one patient (UPN40) and not evaluable in another (UPN41/case 3).

Another interesting finding reported here (case 5) is the first description of mutations in the epigenetic DNA modifiers DNMT3A and TET2 in tumor cells of cHL (see also Supplementary Discussion). While relatively frequent in T-cell lymphomas, mutations of TET2 are less prevalent in the tumor cell clone of B-cell lymphomas (10), and those of DNMT3A are even rarer (21, 22). Furthermore, in diffuse large B-cell lymphomas (DLBCL), presumably clonal DNMT3A mutations were found exclusively in EBV+ cases together with mutations of TET2 (a known tumor suppressor in DLBCL pathogenesis; ref. 23) and in the absence of histone-modifying gene mutations (24). This configuration is similar to cHL case 5, which (in addition to an extensive clonal hematopoiesis of the tumor microenvironment) featured an EBV+ lymphoma cell clone carrying DNMT3A and TET2 comutations but an otherwise almost null exome-wide somatic mutation burden (known to be low in EBV+ cHL; ref. 15). However, additional investigations are required to determine whether DNMT3A and TET2 comutations may play a tumor-cell intrinsic role in the pathogenesis of some EBV+ Hodgkin (and non-Hodgkin) B-cell lymphomas.

Regarding the TET2 disruptive variant observed in the lymphoid microenvironment of case 5, we note that, although Buscarlet and colleagues showed an exclusion of TET2-inactivating mutations from the mature T-cell compartment in healthy individuals with CHIP (25), in case 5 the TET2 variant was presumably subclonal to (i.e., occurred later than) the DNMT3A mutation concomitantly present in the microenvironment (because the VAFs of these two mutations in whole lymph node sections were, respectively, 22% and 32% in the onset sample, and 38% and 27% in the relapse sample). This latter finding is in keeping with the multipotent involvement (T-cell lineage included) of the DNMT3A mutation in the cHL tissue. However, we also note that, in the microdissected tumor microenvironment of case 5, TET2 mutation VAF was not particularly high (8.4%), and hence we cannot formally exclude that it was entirely contributed by non-T cells. We also show that the tumor clones of multiple lymphoid and myeloid neoplasms developing in the same patient with

---

### Table 2. Clinicopathologic features of cHL cases stratified by clonal hematopoiesis distribution in the tissue

<table>
<thead>
<tr>
<th></th>
<th>Extensive* (n = 3)</th>
<th>Absent/nonextensive (n = 37)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 40 patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60 years</td>
<td>1 (33%)</td>
<td>9 (24%)</td>
<td>1</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>2 (67%)</td>
<td>28 (76%)</td>
<td></td>
</tr>
<tr>
<td>EBV status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV+</td>
<td>1 (33%)</td>
<td>8 (22%)</td>
<td>0.55</td>
</tr>
<tr>
<td>EBV-</td>
<td>2 (67%)</td>
<td>29 (78%)</td>
<td></td>
</tr>
<tr>
<td>Histotype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nodular sclerosis</td>
<td>1 (33%)</td>
<td>21 (57%)</td>
<td>0.58</td>
</tr>
<tr>
<td>Mixed cellularity</td>
<td>2 (67%)</td>
<td>12 (32%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0 (0%)</td>
<td>4 (11%)</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early (≤ IIA)</td>
<td>1 (33%)</td>
<td>13 (37%)</td>
<td>1</td>
</tr>
<tr>
<td>Advanced (≥ IIB)</td>
<td>2 (67%)</td>
<td>22 (63%)</td>
<td></td>
</tr>
<tr>
<td>Outcome of first-line therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No progression</td>
<td>0 (0%)</td>
<td>24 (69%)</td>
<td>0.043</td>
</tr>
<tr>
<td>Progression</td>
<td>3 (100%)</td>
<td>11 (31%)</td>
<td></td>
</tr>
<tr>
<td>Follow-up in months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6–35</td>
<td>64 (median)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–149 (range)</td>
<td></td>
<td></td>
<td>0.034</td>
</tr>
</tbody>
</table>

*Extensive: VAF ≥10%.

*By Fisher exact test except for comparison of follow-up where t test was used.

+Nodular sclerosis versus all other subtypes.

+Clinical stage at diagnosis was not available for two patients (UPN26 and UPN40).

+ABVD in all cases, with the following exceptions of little relevance: (i) COPP/ABV in pediatric patient UPN27, not showing clonal hematopoiesis and not progressing after first-line therapy; (ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis and not progressing after first-line therapy; (ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis and not progressing after first-line therapy; (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis and not progressing after first-line therapy).

+Outcome was not available for one patient (UPN40) and not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity.

+Follow-up was not available for one patient (UPN40) and not evaluable in another (UPN41/case 3).
Clonal Hematopoiesis in Classic Hodgkin Lymphoma

clonal hematopoiesis do not necessarily derive all from clonal hematopoiesis, even when (as in case 1 here) the specific mutations driving clonal hematopoiesis in that patient can be present in the tumor clone of the cancer histologies in question and even when such mutations extensively spread through the cell-of-origin lineages and the microenvironment of the neoplasms affecting that patient. Thus, clonal hematopoiesis trajectories must be carefully disentangled to correctly interpret the histogenesis and pathogenesis of multiple blood cancers arising in patients with clonal hematopoiesis.

Finally, the observations made on case 1 raise the question as to whether his AML was related or not to the previous therapy for cHL (see also Supplementary Discussion). The AML clone lacked the genetic signature of typical therapy-related cases (i.e., TP53 or PPMID mutations; complex karyotype and/or loss of chromosomes 5 or 7; refs. 1, 5, 8, 26) and instead carried an NPM1 mutation with normal karyotype, typical of de novo AML (20). These findings may suggest a derivation of the leukemia from a large, and thus high-risk, preexisting CHIP clone (driven by mutant DNMT3A), similar to another recently described lymphoma patient with massive CHIP (sustained by mutant TET2 and ASXL1) who then developed NPM1-mutated AML (11). Further studies are needed to clarify the pathogenesis of such atypical posttherapy AML cases arising from CHIP in patients with lymphoma.

In conclusion, our data demonstrated that clonal hematopoiesis can spread through the neoplastic and/or nonneoplastic tissue components of cHL, with potential implications for the biology and clinical course of this mature B-cell malignancy.

METHODS

Patients’ Samples

We analyzed various types of biological samples that were taken from case 1, as well as lymph node biopsies that were taken from five additional newly processed cHL cases, after the signature of a written informed consent form approved by our hospital review board and in accordance with the Declaration of Helsinki. Lymph node and bone marrow biopsies were fixed in formalin and B5, respectively, and routinely processed according to standard immunohistologic procedures; a portion of the lymph node biopsy was in parallel frozen for laser microdissection (see next paragraph). B cells and T cells of case 1 were purified (to a level ≥98%) from peripheral blood by MACS technology using anti-CD19 and anti-CD3 microbeads (Miltenyi Biotec), respectively, and MS columns following manufacturer recommendations. Genomic DNA was extracted from bone marrow aspirate and peripheral blood samples of case 1 using QIAamp DNA Blood Midi Kit (QIAGEN), and from his purified B and T cells using AllPrep DNA/RNA Mini Kit (QIAGEN). The Gentra Puregene kit (QIAGEN) was instead used to extract DNA from whole biopsy sections of case 5 (formalin-fixed paraffin-embedded at onset; frozen at relapse), case 1 (frozen at onset) and case 2 (frozen at relapse) in order to validate their WES data obtained from microdissected single cells (or, less frequently, as small aggregates of 2–4 cells attached to one another) according to their characteristic cytomorphology and large cell size, and then catapulted into an opaque adhesive cap of a 0.5 mL tube (Zeiss) in groups of 200 to 300 cells per cap. A similar number of non-HRS cells mostly of lymphoid morphology and T-cell immunophenotype (representative example in Fig. 2C; Supplementary Fig. S1) were microdissected from the same sections in areas of 200 to 300 cells and collected in separate caps (some contamination by macrophages, eosinophils, and/or other cell types cannot be excluded, but it would likely have limited relevance, especially in cases showing extensive clonal hematopoiesis with VAF ≥10%). Following DNA extraction using the Gentra Puregene protocol (QIAGEN), whole-genome amplification (WGA) was performed in duplicate from both the HRS and the reactive cell sample as described previously (15).

Targeted Sequencing of Patient Samples

All DNA samples from the six newly processed cases were subjected to molecularly barcoded targeted sequencing of 43 genes recurrently mutated in myeloid neoplasms (QIAseq Targeted DNA Custom Panel–CDHS-163402-1040-Qiagen; Supplementary Table S1A), using 40 to 80 ng of input DNA. In addition, the microdissected HRS and reactive cell WGA DNA (250 ng) of case 1 was subjected to molecularly barcoded targeted sequencing of six JAK–STAT pathway genes recurrently mutated in cHL (QIAseq Targeted DNA Custom Panel–CDHS-168952-163-Qiagen; Supplementary Table S1B). Libraries were generated according to the manufacturer’s instructions and sequenced on an Illumina MiSeq instrument for 2 × 151 cycles, using MiSeq Reagent Kit v2 or v3. The mean unique depth of coverage was 2,856x for the myeloid gene panel and 1,716x for the JAK–STAT pathway gene panel.

Bioinformatics Analysis of Targeted Sequencing Data

Bioinformatics mapping and variant calling of targeted sequencing data [European Nucleotide Archive (ENA) accession number PRJEB42867] was performed with QIAGEN smCounter algorithm v1 or v2 with default settings (27), and variant annotation was performed with Illumina Variant Studio 3.0. Sequencing variants were then subjected to the further following filters and retained only if: (i) variants were predicted to change the gene coding sequence or involved the conserved splice-site (i.e., the four nucleotides surrounding the exon–intron junction); (ii) variants were not present in the Exome Aggregation Consortium (ExAC) database of normal individuals with a population frequency ≥1% (as provided by Illumina Variant Studio 3.0); (iii) variants were present at an allele frequency ≥2%; and (iv) indels were not located in homopolymeric stretches of five nucleotides or longer. In addition, variants called in HRS and reactive lymphoid cell WGA DNA had to be called in both WGA replicates and their mean weighted VAF (reported in Table 1) had to be ≥2%. The SOCS3 disruptive mutation P83AfsX25 (a frameshift deletion of 26 nucleotides) was called in only one of the WGA HRS cell duplicates (VAF 98.6%; 72 unique supporting reads) due to poor coverage of this guanine-cytosine–rich gene in the other duplicate; in the latter, however, visual inspection of the BAM file showed...
We also analyzed our WES data from non-HRS cells of 34 cHL cases that we previously used as a matched counterpart to call somatic mutations in HRS cells of this malignancy (ref. 15; ENA accession number PRJEB25980). DNA from microdissected HRS and reactive cells had been subjected to duplicate WGA and independent WES of the duplicates (referred to as T1-T2 and N1-N2, respectively); furthermore, in most cases (26/34) unamplified genomic DNA from whole exome versions: 1000G: 2015 aug: ExAC: exac03; dbSNP: av00147; cosmic2: cosmic81; clinvar: 20170501; and gnomAD: gnomAD_exome and gnomAD_genome (version n. 41/c) and wAnnovar (29), referring to the following data- sets (except raising the minimum base quality from 0 to 20 in all supporting reads). Variants that had been to pass Varscan2 variant filter with default setting (except the minimum number of variant-supporting reads was changed from 4 to 2, and the minimum variant allele frequency was changed from 5% to 1%); we also retained variants with supporting reads that were nevertheless flagged as “NoReadCounts” by the fpfilter (this is a known bug of Varscan2). Moreover, regarding WGA samples, variants had to be called in both duplicates to efficiently control for false positives potentially introduced by the WGA step as described previously (15). Annotation of the variants was performed by both SNPEff (this is a known bug of Varscan2). Variant metrics were obtained by the bam-read count utility of Varscan2 with default parameters except disabling the base alignment quality computation and increasing the minimum mapping quality from 0 to 20.

Acknowledgments

This work was supported by a grant on cHL to E. Tiacci from AIRC (IG 2019, ID. 23732), a grant on AML to B. Falini from AIRC (IG 2019 number 23604), a grant on AML to B. Falini from ERC (Advanced Grant 2016 number 740230), the Leopard Griffuel prize from ABC, A. Pucciarini, and a grant on cHL to G. Schiavoni from the Department of Medicine, University of Perugia (Ricerca di Base 2017–2019).

Received November 10, 2020; revised January 14, 2021; accepted March 2, 2021; published first April 10, 2021.

REFERENCES

Clonal Hematopoiesis in Classic Hodgkin Lymphoma

Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma

Alessandra Venanzi, Andrea Marra, Gianluca Schiavoni, et al.


Updated version
Access the most recent version of this article at:
doi: 10.1158/2643-3230.BCD-20-0203

Supplementary Material
Access the most recent supplemental material at:
http://bloodcancerdiscov.aacrjournals.org/content/suppl/2021/03/04/2643-3230.BCD-20-0203.DC1

Cited articles
This article cites 29 articles, 9 of which you can access for free at:
http://bloodcancerdiscov.aacrjournals.org/content/2/3/216.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://bloodcancerdiscov.aacrjournals.org/content/2/3/216.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.